Celgene–Exscientia: drug discovery software, 201903–202203 collab $25m upfront + milestones + royalties 3y AI drug discovery partnership

	Period	2019-03-21 � 2022-03-01
	Predecessor	Exscientia–Celgene: investment, 201901 financing round Series B totalling $26m incl new investor Celgene Corp
	Successor	BMS–Exscientia: AI-based drug discovery, 202105– collab $50m upfront + $1.2b milestones + royalties discovery small molecules mutliple disease areas
	Partner, 1st	Celgene Corporation (Nasdaq: CELG)
	Group	Bristol Myers Squibb (BMS) (Group)
	Partner, 2nd	Exscientia Ltd. (ex scientia)
	Group	Recursion Pharmaceuticals (Group)
	Product	Centaur Chemist® AI-based drug discovery platform
	Product 2	drug discovery
	Person	Hamann, Lawrence (Celgene 201903 Corporate VP Chemistry)

Exscientia Ltd.. (3/21/19). "Press Release: Celgene and Exscientia Enter 3-year AI Drug Discovery Collaboration Focused on Accelerating Drug Discovery in Oncology and Autoimmunity". Oxford.

Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program. In addition, Exscientia is due to receive tiered royalties on net sales on any product resulting from the collaboration. Exscientia will apply its full-stack AI drug discovery capabilities to the execution of the entire project – from gene to the drug candidate.

The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates for three therapeutic programmes for Celgene in the areas of oncology and autoimmunity.

Exscientia will use its cutting-edge Centaur Chemist™ AI drug discovery platform, which has demonstrated its unparalleled capabilities on multiple projects and its ability to reduce the timelines by at least three-quarters to discover pre-clinical drug candidates. Applying AI to improve the speed of delivery of new treatments for patients is a key goal of this collaboration.

This deal extends Exscientia’s list of partnerships with blue chip pharma and biotech companies, with existing collaborations involving Roche, GSK, Sanofi and Evotec, cementing Exscientia’s reputation as the partner of choice in the rapidly developing field of AI-driven drug discovery. At the start of this year, the Oxford based Exscientia secured a $26 million Series B investment to expand its capabilities, develop its platform and build its proprietary drug pipeline.

Professor Andrew Hopkins, CEO of Exscientia, commented: “We’re incredibly proud to collaborate with Celgene and to sign another partnership with a key industry player, reinforcing our place at the forefront of AI drug discovery. Today, patients can wait more than ten years from initial drug discovery to its availability as a treatment. With autoimmune diseases and cancer rates increasing, the pharmaceutical industry’s R&D productivity needs to dramatically improve – and technology is a key part of this. Since our pioneering Nature papers in the field, we have been developing our AI platform on the principle that AI combined with human creativity can significantly accelerate the drug discovery process and thus drastically improve access of new drugs to the market. We’re excited to work with Celgene to drive this transformational change in new therapeutic areas.”

“We are tremendously excited to collaborate with such leaders in the development and application of AI tools to accelerate drug discovery. Exscientia have a proven track record of success in this emergent field, and we believe that reducing the number of iteration cycles in optimizing structure-activity and developability relationships through their platform will very favourably impact our ability to deliver high quality development candidates targeting unmet needs in oncology and autoimmunity” says Dr Lawrence Hamann, Corporate Vice President, Chemistry at Celgene.

NOTES FOR EDITORS

About Exscientia

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

Exscientia’s innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.

Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria.

As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.

Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including GSK, Sanofi, Roche and Evotec.

Exscientia has its headquarters in Oxford, UK with offices in the UK, USA and Japan. For more information visit us on www.exscientia.co.uk or follow us on Twitter @exscientialtd.

Media enquiries:

Mark Swindells - Chief Operating Officer
contact@exscientia.co.uk

Edelman PR
Marianne Fekene . +44(0) 7810298448
Camille Oster +44(0) 7812660934
exscientia@edelman.com